GILD vs REGN
GILD and REGN side by side — valuation & fundamentals (public data).
Key statistics
| Metric | GILDGILEAD SCIENCES, INC. | REGNREGENERON PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $212.04B | — |
| P/E (TTM) | 25.2 | 20.5 |
| P/B | 16.26 | — |
| P/S | 7.2x | — |
| Dividend yield | 1.89% | — |
| Revenue | $30.99B(TTM) | $16.90B(TTM) |
| Revenue growth (YoY) | 2.4% | 1.0% |
| Net income | -$3.86B(TTM) | $4.82B(TTM) |
| Earnings growth (YoY) | 1672.9% | 2.1% |
| EPS, diluted | $-3.13(TTM) | $45.24(TTM) |
| EBIT margin | 34.0% | 24.9% |
| ROE | 65.3% | 13.4% |
| ROIC | 25.7% | 9.2% |
| 1y total return | +47.1% | +41.7% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: GILD vs REGN
| 지표 | GILD | REGN |
|---|---|---|
| 최종 가치 | $29.7K | $26.9K |
| 총수익률 | +197.3% | +169.3% |
| CAGR | +11.1% | +10.1% |
| 변동성 | 25.6% | 32.3% |
| 샤프 | 0.38 | 0.33 |
| 소르티노 | 0.56 | 0.49 |
| 최대 낙폭 | -30.5% | -59.7% |
공통 거래일 2600일 기준, 2016-06-29 → 2026-10-30 · 무위험수익률 4.16% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)